Menu

Filtros : "MEDICAMENTO" "FCF" Removidos: "IQ001" "Indexado no MEDLINE" "ESCHERICHIA COLI" "Baruffaldi, Renato" "2001" "Português" "FCF-USP" Limpar

Filtros

Limitar por data

1 - 20 (148 registros)

  • Artigo de periodico

    Overview of pectin-derived Microparticles through microfluidic technology (2024)

    Silva, Pedro Brivaldo Viana da; Fabi, João Paulo

    Fonte: Fluids. Unidade: FCF

    Assuntos: PECTINA, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SILVA, Pedro Brivaldo Viana da e FABI, João Paulo. Overview of pectin-derived Microparticles through microfluidic technology. Fluids, v. 9, p. 1-19 art. 184., 2024Tradução . . Disponível em: https://dx.doi.org/10.3390/fluids9080184. Acesso em: 16 out. 2024.

    • APA

      Silva, P. B. V. da, & Fabi, J. P. (2024). Overview of pectin-derived Microparticles through microfluidic technology. Fluids, 9, 1-19 art. 184. doi:10.3390/fluids9080184

    • NLM

      Silva PBV da, Fabi JP. Overview of pectin-derived Microparticles through microfluidic technology [Internet]. Fluids. 2024 ; 9 1-19 art. 184.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.3390/fluids9080184

    • Vancouver

      Silva PBV da, Fabi JP. Overview of pectin-derived Microparticles through microfluidic technology [Internet]. Fluids. 2024 ; 9 1-19 art. 184.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.3390/fluids9080184

  • Artigo de periodico

    Dendrimers as drug delivery systems for oncotherapy: current status of promising applications (2024)

    Sueyoshi, Sophia Mikiko Oliveira; Silva, João Vitor da ; Guizze, Felipe; Giarolla, Jeanine

    Fonte: International Journal of Pharmaceutics. Unidade: FCF

    Assuntos: MEDICAMENTO, NEOPLASIAS

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SUEYOSHI, Sophia Mikiko Oliveira et al. Dendrimers as drug delivery systems for oncotherapy: current status of promising applications. International Journal of Pharmaceutics, v. 663, p. 1-33 art. 124573, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.ijpharm.2024.124573. Acesso em: 16 out. 2024.

    • APA

      Sueyoshi, S. M. O., Silva, J. V. da, Guizze, F., & Giarolla, J. (2024). Dendrimers as drug delivery systems for oncotherapy: current status of promising applications. International Journal of Pharmaceutics, 663, 1-33 art. 124573. doi:10.1016/j.ijpharm.2024.124573

    • NLM

      Sueyoshi SMO, Silva JV da, Guizze F, Giarolla J. Dendrimers as drug delivery systems for oncotherapy: current status of promising applications [Internet]. International Journal of Pharmaceutics. 2024 ; 663 1-33 art. 124573.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.ijpharm.2024.124573

    • Vancouver

      Sueyoshi SMO, Silva JV da, Guizze F, Giarolla J. Dendrimers as drug delivery systems for oncotherapy: current status of promising applications [Internet]. International Journal of Pharmaceutics. 2024 ; 663 1-33 art. 124573.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.ijpharm.2024.124573

  • Artigo de periodico

    Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin (2024)

    Richter, Luca Maurice ; Al-Gousous, Jozef ; Araujo, Gabriel Lima Barros de ; Davies, Neal M ; Löbenberg, Raimar

    Fonte: Journal of Drug Delivery Science and Technology. Unidade: FCF

    Assuntos: DEPRESSÃO, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      RICHTER, Luca Maurice et al. Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin. Journal of Drug Delivery Science and Technology, v. 92, p. 1-14, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.jddst.2023.105305. Acesso em: 16 out. 2024.

    • APA

      Richter, L. M., Al-Gousous, J., Araujo, G. L. B. de, Davies, N. M., & Löbenberg, R. (2024). Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin. Journal of Drug Delivery Science and Technology, 92, 1-14. doi:10.1016/j.jddst.2023.105305

    • NLM

      Richter LM, Al-Gousous J, Araujo GLB de, Davies NM, Löbenberg R. Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin [Internet]. Journal of Drug Delivery Science and Technology. 2024 ; 92 1-14.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.jddst.2023.105305

    • Vancouver

      Richter LM, Al-Gousous J, Araujo GLB de, Davies NM, Löbenberg R. Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin [Internet]. Journal of Drug Delivery Science and Technology. 2024 ; 92 1-14.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.jddst.2023.105305

  • Artigo de periodico

    SETDB1 as a cancer target: challenges and perspectives in drug design (2024)

    Hassanie, Haifa ; Penteado, André Berndt ; Almeida, Larissa Costa de ; Calil, Raisa Ludmila; Emery, Flavio da Silva ; Costa-Lotufo, Letícia Veras ; Trossini, Gustavo Henrique Goulart

    Fonte: RSC Medicinal Chemistry. Unidades: FCFRP, ICB, FCF

    Assuntos: NEOPLASIAS, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      HASSANIE, Haifa et al. SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, v. 15, n. 5, p. 1424-1451, 2024Tradução . . Disponível em: https://dx.doi.org/10.1039/D3MD00366C. Acesso em: 16 out. 2024.

    • APA

      Hassanie, H., Penteado, A. B., Almeida, L. C. de, Calil, R. L., Emery, F. da S., Costa-Lotufo, L. V., & Trossini, G. H. G. (2024). SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, 15( 5), 1424-1451. doi:10.1039/D3MD00366C

    • NLM

      Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Costa-Lotufo LV, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1039/D3MD00366C

    • Vancouver

      Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Costa-Lotufo LV, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1039/D3MD00366C

  • Artigo de periodico

    Evaluation of drug litigation against the Campinas municipal health system from 2017 to 2021 (2024)

    Oliveira, Stefane Cristina Paixão ; Moriel, Patricia ; Bonafé, Michelle; Visacri, Marilia Berlofa

    Fonte: Scientific Reports. Unidade: FCF

    Assuntos: SAÚDE PÚBLICA, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      OLIVEIRA, Stefane Cristina Paixão et al. Evaluation of drug litigation against the Campinas municipal health system from 2017 to 2021. Scientific Reports, v. 14, p. 1-11 art. 18764, 2024Tradução . . Disponível em: https://dx.doi.org/10.1038/s41598-024-68988-2. Acesso em: 16 out. 2024.

    • APA

      Oliveira, S. C. P., Moriel, P., Bonafé, M., & Visacri, M. B. (2024). Evaluation of drug litigation against the Campinas municipal health system from 2017 to 2021. Scientific Reports, 14, 1-11 art. 18764. doi:10.1038/s41598-024-68988-2

    • NLM

      Oliveira SCP, Moriel P, Bonafé M, Visacri MB. Evaluation of drug litigation against the Campinas municipal health system from 2017 to 2021 [Internet]. Scientific Reports. 2024 ; 14 1-11 art. 18764.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1038/s41598-024-68988-2

    • Vancouver

      Oliveira SCP, Moriel P, Bonafé M, Visacri MB. Evaluation of drug litigation against the Campinas municipal health system from 2017 to 2021 [Internet]. Scientific Reports. 2024 ; 14 1-11 art. 18764.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1038/s41598-024-68988-2

  • Artigo de periodico

    Key performance indicators for pharmaceutical services: a systematic review (2024)

    Souza, Julie Faria Ferreira de; Fernandes, Brígida Dias ; Rotta, Inajara ; Visacri, Marilia Berlofa ; Lima, Tácio de Mendonça

    Fonte: Exploratory Research in Clinical and Social Pharmacy. Unidade: FCF

    Assuntos: SERVIÇOS FARMACÊUTICOS, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SOUZA, Julie Faria Ferreira de et al. Key performance indicators for pharmaceutical services: a systematic review. Exploratory Research in Clinical and Social Pharmacy, v. 14, p. 1-8, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.rcsop.2024.100441. Acesso em: 16 out. 2024.

    • APA

      Souza, J. F. F. de, Fernandes, B. D., Rotta, I., Visacri, M. B., & Lima, T. de M. (2024). Key performance indicators for pharmaceutical services: a systematic review. Exploratory Research in Clinical and Social Pharmacy, 14, 1-8. doi:10.1016/j.rcsop.2024.100441

    • NLM

      Souza JFF de, Fernandes BD, Rotta I, Visacri MB, Lima T de M. Key performance indicators for pharmaceutical services: a systematic review [Internet]. Exploratory Research in Clinical and Social Pharmacy. 2024 ; 14 1-8.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.rcsop.2024.100441

    • Vancouver

      Souza JFF de, Fernandes BD, Rotta I, Visacri MB, Lima T de M. Key performance indicators for pharmaceutical services: a systematic review [Internet]. Exploratory Research in Clinical and Social Pharmacy. 2024 ; 14 1-8.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.rcsop.2024.100441

  • Artigo de periodico

    HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review (2024)

    Felippini, Arturo; Biglia, Luiza Vasconcelos; Lima, Tácio de Mendonça ; Aguiar, Patrícia Melo

    Fonte: Health Policy. Unidade: FCF

    Assuntos: DOENÇAS RARAS, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      FELIPPINI, Arturo et al. HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review. Health Policy, v. 144, p. 1-8 art. 105080, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.healthpol.2024.105080. Acesso em: 16 out. 2024.

    • APA

      Felippini, A., Biglia, L. V., Lima, T. de M., & Aguiar, P. M. (2024). HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review. Health Policy, 144, 1-8 art. 105080. doi:10.1016/j.healthpol.2024.105080

    • NLM

      Felippini A, Biglia LV, Lima T de M, Aguiar PM. HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review [Internet]. Health Policy. 2024 ; 144 1-8 art. 105080.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.healthpol.2024.105080

    • Vancouver

      Felippini A, Biglia LV, Lima T de M, Aguiar PM. HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review [Internet]. Health Policy. 2024 ; 144 1-8 art. 105080.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.healthpol.2024.105080

  • Artigo de periodico

    Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods – Uncertainties arising from sampling and analytical steps (2024)

    Martins, Maisa Torres; Lourenço, Felipe Rebello

    Fonte: Journal of Pharmaceutical and Biomedical Analysis. Unidade: FCF

    Assuntos: MEDICAMENTO, MÉTODO DE MONTE CARLO, MEDIÇÃO DE RISCO

    PrivadoAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      MARTINS, Maisa Torres e LOURENÇO, Felipe Rebello. Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods – Uncertainties arising from sampling and analytical steps. Journal of Pharmaceutical and Biomedical Analysis, v. 238, p. 1-8 art. 115857, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.jpba.2023.115857. Acesso em: 16 out. 2024.

    • APA

      Martins, M. T., & Lourenço, F. R. (2024). Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods – Uncertainties arising from sampling and analytical steps. Journal of Pharmaceutical and Biomedical Analysis, 238, 1-8 art. 115857. doi:10.1016/j.jpba.2023.115857

    • NLM

      Martins MT, Lourenço FR. Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods – Uncertainties arising from sampling and analytical steps [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2024 ; 238 1-8 art. 115857.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.jpba.2023.115857

    • Vancouver

      Martins MT, Lourenço FR. Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods – Uncertainties arising from sampling and analytical steps [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2024 ; 238 1-8 art. 115857.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.jpba.2023.115857

  • Trabalho de evento-resumo

    Molecular modeling and structural comparison of leishmania sirtuin 2 enzymes, an epigenetic target in drug discovery (2024)

    Penteado, André Berndt ; Trossini, Gustavo Henrique Goulart

    Fonte: Anais. Nome do evento: Reunião Anual da Sociedade Brasileira de Química - RASBQ. Unidade: FCF

    Assuntos: LEISHMANIA, MEDICAMENTO

    Acesso à fonteComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      PENTEADO, André Berndt e TROSSINI, Gustavo Henrique Goulart. Molecular modeling and structural comparison of leishmania sirtuin 2 enzymes, an epigenetic target in drug discovery. 2024, Anais.. São Paulo: Sociedade Brasileira de Química - SBQ, 2024. Disponível em: https://www.eventweb.com.br/rasbq2024/home-event/schedule.php?q=&area=todas&sessao=todas&tipo=1#trabalhos. Acesso em: 16 out. 2024.

    • APA

      Penteado, A. B., & Trossini, G. H. G. (2024). Molecular modeling and structural comparison of leishmania sirtuin 2 enzymes, an epigenetic target in drug discovery. In Anais. São Paulo: Sociedade Brasileira de Química - SBQ. Recuperado de https://www.eventweb.com.br/rasbq2024/home-event/schedule.php?q=&area=todas&sessao=todas&tipo=1#trabalhos

    • NLM

      Penteado AB, Trossini GHG. Molecular modeling and structural comparison of leishmania sirtuin 2 enzymes, an epigenetic target in drug discovery [Internet]. Anais. 2024 ;[citado 2024 out. 16 ] Available from: https://www.eventweb.com.br/rasbq2024/home-event/schedule.php?q=&area=todas&sessao=todas&tipo=1#trabalhos

    • Vancouver

      Penteado AB, Trossini GHG. Molecular modeling and structural comparison of leishmania sirtuin 2 enzymes, an epigenetic target in drug discovery [Internet]. Anais. 2024 ;[citado 2024 out. 16 ] Available from: https://www.eventweb.com.br/rasbq2024/home-event/schedule.php?q=&area=todas&sessao=todas&tipo=1#trabalhos

  • Artigo de periodico

    Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products (2024)

    Lopes, Ivone de Jesus do Nascimento; Fujimori, Sérgio Kazumasa; Mendes, Thamara de Carvalho; Almeida, Rayza Adrielle Dias de; Sousa, Flávia Furtado de Mendonça de; Oliveira, Camila Areias de; Nascimento, Diogo Dibo do; Lourenço, Felipe Rebello ; Rodrigues, Maria Isabel; Prado, Livia Deris

    Fonte: Microchemical Journal. Unidade: FCF

    Assuntos: CROMATOGRAFIA LÍQUIDA DE ALTA EFICIÊNCIA, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      LOPES, Ivone de Jesus do Nascimento et al. Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products. Microchemical Journal, v. 199, p. 1-9 art. 109939, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.microc.2024.109939. Acesso em: 16 out. 2024.

    • APA

      Lopes, I. de J. do N., Fujimori, S. K., Mendes, T. de C., Almeida, R. A. D. de, Sousa, F. F. de M. de, Oliveira, C. A. de, et al. (2024). Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products. Microchemical Journal, 199, 1-9 art. 109939. doi:10.1016/j.microc.2024.109939

    • NLM

      Lopes I de J do N, Fujimori SK, Mendes T de C, Almeida RAD de, Sousa FF de M de, Oliveira CA de, Nascimento DD do, Lourenço FR, Rodrigues MI, Prado LD. Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products [Internet]. Microchemical Journal. 2024 ; 199 1-9 art. 109939.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.microc.2024.109939

    • Vancouver

      Lopes I de J do N, Fujimori SK, Mendes T de C, Almeida RAD de, Sousa FF de M de, Oliveira CA de, Nascimento DD do, Lourenço FR, Rodrigues MI, Prado LD. Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products [Internet]. Microchemical Journal. 2024 ; 199 1-9 art. 109939.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.microc.2024.109939

  • Artigo de periodico

    PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase (2024)

    Obreque, Karin Mariana Torres ; Kleingesinds, Eduardo Krebs ; Santos, João Henrique Picado Madalena ; Carretero, Gustavo Penteado Battesini ; Cunha, Jheniffer Rabelo ; Converti, Attilio ; Monteiro, Gisele ; Pessoa Junior, Adalberto ; Rangel-Yagui, Carlota de Oliveira

    Fonte: Preparative Biochemistry & Biotechnology. Unidade: FCF

    Assuntos: TERMODINÂMICA, MEDICAMENTO

    PrivadoAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      OBREQUE, Karin Mariana Torres et al. PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase. Preparative Biochemistry & Biotechnology, v. 54, n. 4, p. 503-513, 2024Tradução . . Disponível em: https://doi.org/10.1080/10826068.2023.2249100. Acesso em: 16 out. 2024.

    • APA

      Obreque, K. M. T., Kleingesinds, E. K., Santos, J. H. P. M., Carretero, G. P. B., Cunha, J. R., Converti, A., et al. (2024). PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase. Preparative Biochemistry & Biotechnology, 54( 4), 503-513. doi:10.1080/10826068.2023.2249100

    • NLM

      Obreque KMT, Kleingesinds EK, Santos JHPM, Carretero GPB, Cunha JR, Converti A, Monteiro G, Pessoa Junior A, Rangel-Yagui C de O. PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase [Internet]. Preparative Biochemistry & Biotechnology. 2024 ; 54( 4): 503-513.[citado 2024 out. 16 ] Available from: https://doi.org/10.1080/10826068.2023.2249100

    • Vancouver

      Obreque KMT, Kleingesinds EK, Santos JHPM, Carretero GPB, Cunha JR, Converti A, Monteiro G, Pessoa Junior A, Rangel-Yagui C de O. PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase [Internet]. Preparative Biochemistry & Biotechnology. 2024 ; 54( 4): 503-513.[citado 2024 out. 16 ] Available from: https://doi.org/10.1080/10826068.2023.2249100

  • Artigo de periodico

    Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets (2023)

    Souza, Mariana Laureano de ; Lapierre, thibault Joseph William Jacques Dit ; Marques, Gabriel Vitor de Lima; Ferraz, Witor Ribeiro ; Penteado, André Berndt ; Trossini, Gustavo Henrique Goulart ; Murta, Silvane Maria Fonseca; Oliveira, Renata Barbosa de; Rezende Junior, Celso de Oliveira ; Ferreira, Rafaela Salgado

    Fonte: Expert Opinion on Therapeutic Targets. Unidade: FCF

    Assuntos: DOENÇA DE CHAGAS, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SOUZA, Mariana Laureano de et al. Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets. Expert Opinion on Therapeutic Targets, v. 27, p. 911-925, 2023Tradução . . Disponível em: https://dx.doi.org/10.1080/14728222.2023.2264512. Acesso em: 16 out. 2024.

    • APA

      Souza, M. L. de, Lapierre, thibault J. W. J. D., Marques, G. V. de L., Ferraz, W. R., Penteado, A. B., Trossini, G. H. G., et al. (2023). Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets. Expert Opinion on Therapeutic Targets, 27, 911-925. doi:10.1080/14728222.2023.2264512

    • NLM

      Souza ML de, Lapierre thibault JWJD, Marques GV de L, Ferraz WR, Penteado AB, Trossini GHG, Murta SMF, Oliveira RB de, Rezende Junior C de O, Ferreira RS. Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets [Internet]. Expert Opinion on Therapeutic Targets. 2023 ; 27 911-925.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1080/14728222.2023.2264512

    • Vancouver

      Souza ML de, Lapierre thibault JWJD, Marques GV de L, Ferraz WR, Penteado AB, Trossini GHG, Murta SMF, Oliveira RB de, Rezende Junior C de O, Ferreira RS. Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets [Internet]. Expert Opinion on Therapeutic Targets. 2023 ; 27 911-925.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1080/14728222.2023.2264512

  • Artigo de periodico

    Polymersomes for protein drug delivery across intestinal mucosa (2023)

    Cachumba, Jorge Javier Muso; Feng, Sa; Belaid, Mona; Zhang, Yunyue; Rangel-Yagui, Carlota de Oliveira ; Vllasaliu, Driton

    Fonte: International Journal of Pharmaceutics. Unidade: FCF

    Assuntos: ENTEROPATIAS INFLAMATÓRIAS, MEDICAMENTO, BIOFARMACOLOGIA

    PrivadoAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      CACHUMBA, Jorge Javier Muso et al. Polymersomes for protein drug delivery across intestinal mucosa. International Journal of Pharmaceutics, v. 648, p. 1-9 art. 123613, 2023Tradução . . Disponível em: https://dx.doi.org/10.1016/j.ijpharm.2023.123613. Acesso em: 16 out. 2024.

    • APA

      Cachumba, J. J. M., Feng, S., Belaid, M., Zhang, Y., Rangel-Yagui, C. de O., & Vllasaliu, D. (2023). Polymersomes for protein drug delivery across intestinal mucosa. International Journal of Pharmaceutics, 648, 1-9 art. 123613. doi:10.1016/j.ijpharm.2023.123613

    • NLM

      Cachumba JJM, Feng S, Belaid M, Zhang Y, Rangel-Yagui C de O, Vllasaliu D. Polymersomes for protein drug delivery across intestinal mucosa [Internet]. International Journal of Pharmaceutics. 2023 ; 648 1-9 art. 123613.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.ijpharm.2023.123613

    • Vancouver

      Cachumba JJM, Feng S, Belaid M, Zhang Y, Rangel-Yagui C de O, Vllasaliu D. Polymersomes for protein drug delivery across intestinal mucosa [Internet]. International Journal of Pharmaceutics. 2023 ; 648 1-9 art. 123613.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1016/j.ijpharm.2023.123613

  • Artigo de periodico

    Risk of false conformity decisions in LAL gel-clot test due to false-negative results (2023)

    Couto, Aldo Renato; Passarin, Paula Beatriz Silva ; Lourenço, Felipe Rebello

    Fonte: Chemometrics and Intelligent Laboratory Systems. Unidade: FCF

    Assuntos: ENDOTOXINAS, MEDICAMENTO

    PrivadoAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      COUTO, Aldo Renato e PASSARIN, Paula Beatriz Silva e LOURENÇO, Felipe Rebello. Risk of false conformity decisions in LAL gel-clot test due to false-negative results. Chemometrics and Intelligent Laboratory Systems, v. 234, p. 1-6 art. 104760, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.chemolab.2023.104760. Acesso em: 16 out. 2024.

    • APA

      Couto, A. R., Passarin, P. B. S., & Lourenço, F. R. (2023). Risk of false conformity decisions in LAL gel-clot test due to false-negative results. Chemometrics and Intelligent Laboratory Systems, 234, 1-6 art. 104760. doi:10.1016/j.chemolab.2023.104760

    • NLM

      Couto AR, Passarin PBS, Lourenço FR. Risk of false conformity decisions in LAL gel-clot test due to false-negative results [Internet]. Chemometrics and Intelligent Laboratory Systems. 2023 ; 234 1-6 art. 104760.[citado 2024 out. 16 ] Available from: https://doi.org/10.1016/j.chemolab.2023.104760

    • Vancouver

      Couto AR, Passarin PBS, Lourenço FR. Risk of false conformity decisions in LAL gel-clot test due to false-negative results [Internet]. Chemometrics and Intelligent Laboratory Systems. 2023 ; 234 1-6 art. 104760.[citado 2024 out. 16 ] Available from: https://doi.org/10.1016/j.chemolab.2023.104760

  • Artigo de periodico

    Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid (2023)

    Yousef, Malaz ; Le, Tyson S; Zuo, Jieyu; Park, Chulhun; Bou-Chacra, Nadia Araci ; Davies, Neal M; Löbenberg, Raimar

    Fonte: Research in Pharmaceutical Sciences. Unidade: FCF

    Assuntos: LISOSSOMOS, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      YOUSEF, Malaz et al. Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid. Research in Pharmaceutical Sciences, v. 18, n. 1, p. 1-15, 2023Tradução . . Disponível em: https://doi.org/10.4103/1735-5362.363591. Acesso em: 16 out. 2024.

    • APA

      Yousef, M., Le, T. S., Zuo, J., Park, C., Bou-Chacra, N. A., Davies, N. M., & Löbenberg, R. (2023). Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid. Research in Pharmaceutical Sciences, 18( 1), 1-15. doi:10.4103/1735-5362.363591

    • NLM

      Yousef M, Le TS, Zuo J, Park C, Bou-Chacra NA, Davies NM, Löbenberg R. Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid [Internet]. Research in Pharmaceutical Sciences. 2023 ; 18( 1): 1-15.[citado 2024 out. 16 ] Available from: https://doi.org/10.4103/1735-5362.363591

    • Vancouver

      Yousef M, Le TS, Zuo J, Park C, Bou-Chacra NA, Davies NM, Löbenberg R. Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid [Internet]. Research in Pharmaceutical Sciences. 2023 ; 18( 1): 1-15.[citado 2024 out. 16 ] Available from: https://doi.org/10.4103/1735-5362.363591

  • Artigo de periodico

    Pteridine reductase (PTR1): initial structureactivity relationships studies of potential leishmanicidal arylindole derivatives compounds (2023)

    Silva, J.V; Sueyoshia, S; Snape, T.J; Lal, S; Giarolla, Jeanine

    Fonte: SAR and QSAR in Environmental Research. Unidade: FCF

    Assuntos: LEISHMANIA, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SILVA, J.V et al. Pteridine reductase (PTR1): initial structureactivity relationships studies of potential leishmanicidal arylindole derivatives compounds. SAR and QSAR in Environmental Research, v. 34, n. 8, p. 661–687, 2023Tradução . . Disponível em: https://dx.doi.org/10.1080/1062936X.2023.2247331. Acesso em: 16 out. 2024.

    • APA

      Silva, J. V., Sueyoshia, S., Snape, T. J., Lal, S., & Giarolla, J. (2023). Pteridine reductase (PTR1): initial structureactivity relationships studies of potential leishmanicidal arylindole derivatives compounds. SAR and QSAR in Environmental Research, 34( 8), 661–687. doi:10.1080/1062936X.2023.2247331

    • NLM

      Silva JV, Sueyoshia S, Snape TJ, Lal S, Giarolla J. Pteridine reductase (PTR1): initial structureactivity relationships studies of potential leishmanicidal arylindole derivatives compounds [Internet]. SAR and QSAR in Environmental Research. 2023 ; 34( 8): 661–687.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1080/1062936X.2023.2247331

    • Vancouver

      Silva JV, Sueyoshia S, Snape TJ, Lal S, Giarolla J. Pteridine reductase (PTR1): initial structureactivity relationships studies of potential leishmanicidal arylindole derivatives compounds [Internet]. SAR and QSAR in Environmental Research. 2023 ; 34( 8): 661–687.[citado 2024 out. 16 ] Available from: https://dx.doi.org/10.1080/1062936X.2023.2247331

  • Artigo de periodico

    Counterfeit medicines: relevance, consequences and strategies to combat the global crisis (2023)

    Lima, Marcela Bittar Araujo; Yonamine, Maurício

    Fonte: Brazilian Journal of Pharmaceutical Sciences. Unidade: FCF

    Assuntos: MEDICAMENTO, FALSIFICAÇÃO

    Versão PublicadaAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      LIMA, Marcela Bittar Araujo e YONAMINE, Maurício. Counterfeit medicines: relevance, consequences and strategies to combat the global crisis. Brazilian Journal of Pharmaceutical Sciences, v. 59, p. 1-16 art. e20402, 2023Tradução . . Disponível em: https://doi.org/10.1590/s2175-97902023e20402. Acesso em: 16 out. 2024.

    • APA

      Lima, M. B. A., & Yonamine, M. (2023). Counterfeit medicines: relevance, consequences and strategies to combat the global crisis. Brazilian Journal of Pharmaceutical Sciences, 59, 1-16 art. e20402. doi:10.1590/s2175-97902023e20402

    • NLM

      Lima MBA, Yonamine M. Counterfeit medicines: relevance, consequences and strategies to combat the global crisis [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2023 ; 59 1-16 art. e20402.[citado 2024 out. 16 ] Available from: https://doi.org/10.1590/s2175-97902023e20402

    • Vancouver

      Lima MBA, Yonamine M. Counterfeit medicines: relevance, consequences and strategies to combat the global crisis [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2023 ; 59 1-16 art. e20402.[citado 2024 out. 16 ] Available from: https://doi.org/10.1590/s2175-97902023e20402

  • Artigo de periodico

    2,3-Diarylindoles as COX-2 Inhibitors: exploring the structure-activity relationship through molecular docking simulations (2023)

    Cuppoloni, Andréa; Silva, João Vitor da ; Snape, Timothy James ; Lal, Samridhi ; Giarolla, Jeanine

    Fonte: Current Topics in Medicinal Chemistry. Unidade: FCF

    Assuntos: MEDICAMENTO, METABOLISMO

    PrivadoAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      CUPPOLONI, Andréa et al. 2,3-Diarylindoles as COX-2 Inhibitors: exploring the structure-activity relationship through molecular docking simulations. Current Topics in Medicinal Chemistry, v. 23, n. 12, p. 1081-1089, 2023Tradução . . Disponível em: https://doi.org/10.2174/1568026623666230207120752. Acesso em: 16 out. 2024.

    • APA

      Cuppoloni, A., Silva, J. V. da, Snape, T. J., Lal, S., & Giarolla, J. (2023). 2,3-Diarylindoles as COX-2 Inhibitors: exploring the structure-activity relationship through molecular docking simulations. Current Topics in Medicinal Chemistry, 23( 12), 1081-1089. doi:10.2174/1568026623666230207120752

    • NLM

      Cuppoloni A, Silva JV da, Snape TJ, Lal S, Giarolla J. 2,3-Diarylindoles as COX-2 Inhibitors: exploring the structure-activity relationship through molecular docking simulations [Internet]. Current Topics in Medicinal Chemistry. 2023 ; 23( 12): 1081-1089.[citado 2024 out. 16 ] Available from: https://doi.org/10.2174/1568026623666230207120752

    • Vancouver

      Cuppoloni A, Silva JV da, Snape TJ, Lal S, Giarolla J. 2,3-Diarylindoles as COX-2 Inhibitors: exploring the structure-activity relationship through molecular docking simulations [Internet]. Current Topics in Medicinal Chemistry. 2023 ; 23( 12): 1081-1089.[citado 2024 out. 16 ] Available from: https://doi.org/10.2174/1568026623666230207120752

  • Trabalho de evento-resumo periodico

    Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil (2023)

    Biglia, Luiza Vasconcelos ; Felippini, A; Ribeiro, T. B; Lima, T. D. M; Aguiar, Patrícia Melo

    Fonte: Value in Health. Nome do evento: ISPOR Europe. Unidade: FCF

    Assuntos: DOENÇAS RARAS, MEDICAMENTO

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      BIGLIA, Luiza Vasconcelos et al. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jval.2023.09.1783. Acesso em: 16 out. 2024. , 2023

    • APA

      Biglia, L. V., Felippini, A., Ribeiro, T. B., Lima, T. D. M., & Aguiar, P. M. (2023). Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.1016/j.jval.2023.09.1783

    • NLM

      Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2024 out. 16 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783

    • Vancouver

      Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2024 out. 16 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783

  • Trabalho de evento-resumo

    Machine learning methods applied for the prediction of biological activities of triple reuptake inhibitors (2023)

    Sousa, Gustavo Henrique Marques; Gomes, Renan Augusto ; Oliveira, Eliseu Ortega de; Trossini, Gustavo Henrique Goulart

    Fonte: Anais. Nome do evento: Reunião Anual da Sociedade Brasileira de Química/RASBQ. Unidade: FCF

    Assuntos: DEPRESSÃO, MEDICAMENTO

    Versão PublicadaAcesso à fonteComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SOUSA, Gustavo Henrique Marques et al. Machine learning methods applied for the prediction of biological activities of triple reuptake inhibitors. 2023, Anais.. São Paulo: Sociedade Brasileira de Química/SBQ, 2023. Disponível em: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf. Acesso em: 16 out. 2024.

    • APA

      Sousa, G. H. M., Gomes, R. A., Oliveira, E. O. de, & Trossini, G. H. G. (2023). Machine learning methods applied for the prediction of biological activities of triple reuptake inhibitors. In Anais. São Paulo: Sociedade Brasileira de Química/SBQ. Recuperado de https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf

    • NLM

      Sousa GHM, Gomes RA, Oliveira EO de, Trossini GHG. Machine learning methods applied for the prediction of biological activities of triple reuptake inhibitors [Internet]. Anais. 2023 ;[citado 2024 out. 16 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf

    • Vancouver

      Sousa GHM, Gomes RA, Oliveira EO de, Trossini GHG. Machine learning methods applied for the prediction of biological activities of triple reuptake inhibitors [Internet]. Anais. 2023 ;[citado 2024 out. 16 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf

1 - 20 (148 registros)

Biblioteca Digital de Produção Intelectual da Universidade de São Paulo     2012 - 2024